Research programme: small molecule therapeutics - Gain Therapeutics
Latest Information Update: 17 Mar 2022
At a glance
- Originator Gain Therapeutics
- Developer Gain Therapeutics; Institute for Research in Biomedicine; Neurocentro
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Glucosylceramidase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Gangliosidoses; Gaucher's disease; Mucopolysaccharidosis IV; Parkinson's disease
- Research Lysosomal storage diseases; Neurodegenerative disorders
Most Recent Events
- 15 Mar 2022 Preclinical trials in Alzheimer's disease in Switzerland (PO) before March 2022
- 15 Mar 2022 Preclinical trials in Parkinson's disease in Switzerland (PO) before March 2022
- 15 Mar 2022 Pharmacodynamics data from preclinical studies in Parkinson’s and Alzheimer’s Disease released by Gain Therapeutics